Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Wells Fargo Maintains Overweight on Tandem Diabetes Care, Raises Price Target to $50

Author: Benzinga Newsdesk | May 03, 2024 02:06pm
Wells Fargo analyst Larry Biegelsen maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Overweight and raises the price target from $45 to $50.

Posted In: TNDM